Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers process development and optimization, analytical services, and scale-up services for small molecule drug products throughout the pre-clinical and clinical stage; and ton-scale manufacturing services for registered starting materials, advanced intermediates, and active pharmaceutical ingredients. It also engages in pre-formulation and formulation development; chemical macromolecule contract development manufacture organization (CMDO) solutions for polypeptides, oligonucleotides, glycans, toxins-linkers and other macromolecules; biosynthesis solutions; biologics CDMO solutions for monoclonal antibodies and antibody-drug conjugates; and contract research organization solutions and messenger RNA solution. In addition, the company is involved in development and drug product manufacturing; pharmaceutical analysis and testing services; medical research and development; manufacturing, sale, and development of medicine raw materials and relevant products; sale of drug products; pharmaceuticals and chemical manufacturing; wholesaling and retailing of drugs; sale, import and export trade; information technology; technology development; and research and experimental development. The company was founded in 1998 and is headquartered in Tianjin, China.
Metrics to compare | 002821 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship002821PeersSector | |
---|---|---|---|---|
P/E Ratio | 37.9x | 20.2x | −0.6x | |
PEG Ratio | −0.52 | 0.35 | 0.00 | |
Price/Book | 1.8x | 2.9x | 2.6x | |
Price / LTM Sales | 5.2x | 5.3x | 3.2x | |
Upside (Analyst Target) | 19.2% | 18.4% | 40.6% | |
Fair Value Upside | Unlock | 4.1% | 7.1% | Unlock |